MTOR and hepatocellular carcinoma: Our result showing stronger p-mTOR expression in metastatic RCC and HCC than in their primary counterparts is consistent with the previous immunohistochemical data [33] and supports the rationale for clinical use of mTOR inhibitors in advanced RCC and HCC [34, 35].